Skip to main content
Delfa

← Trials/Trial dossier/NCT00703430

UnknownPhase NA

Memantine on Aggression and Agitation of Alzheimer's Disease (AD)

The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study

Lead sponsor

Peking University

Asset

Memantine

Listed sites

1

Recruiting sites

1

Enrollment

50

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•CMAI score

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCN-IIT-12292
NCT IDNCT00703430

Timeline

Milestones

Study start2008-03 (month precision)
Study first posted2008-06-23estimated
Last update posted2013-01-25estimated
Primary completion2013-12estimated (month precision)
Study completion2014-06estimated (month precision)

Assets

Drug assets

Memantine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Written informed consent

2. Clinical diagnosis of Alzheimer's disease.

3. Having at least a minimum aggression score on the Cohen-Mansfield Agitation Inventory (CMAI): a score of ≥ 4 on at least 1 aggressive item, or a score of 3 on at least 2 aggressive items, or a score of 2 on at least 3 aggressive items, or 2 aggressive items occurring at a frequency of 2 and 1 at a frequency of 3.

4. Availability of a responsible family member or carer to ensure treatment compliance and provide information for informant assessments

Exclusion criteria

1. Unavailability of a responsible family member or carer

2. Severe renal impairment.

3. History of seizures

4. Diagnosis of any concomitant life threatening illness.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Behavior / neuropsychiatric
2
Other (unclassified)
2

Behavior / neuropsychiatric

2 endpoints
Primary/protocol endpoint

CMAI score

Time frame:12 weeks

descriptive

Secondary/protocol endpoint

NPI score

Time frame:12 weeks

Neuropsychiatric Inventory (NPI)

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

CBI score

Time frame:12 weeks

descriptive

Secondary/protocol endpoint/low confidence

RUD

Time frame:12 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.